End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
14.33 CNY | +3.54% | +2.43% | -39.05% |
Apr. 26 | Walvax Biotechnology's Profit Drops 92%, Operating Income Slids 28% in Q1 2024 | MT |
Apr. 25 | Walvax Biotechnology's Unit to End COVID-19 Vaccine Trial | MT |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- With an enterprise value anticipated at 4.54 times the sales for the current fiscal year, the company turns out to be overvalued.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-39.05% | 3.06B | C+ | ||
-4.66% | 87.53B | A- | ||
+1.32% | 40.42B | A- | ||
-19.27% | 29.48B | B- | ||
+57.86% | 25.43B | A | ||
-17.69% | 11.49B | B- | ||
-43.00% | 11.3B | B | ||
-9.14% | 11.1B | D+ | ||
+5.24% | 8.75B | B+ | ||
-8.42% | 7.99B | B- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- 300142 Stock
- Ratings Walvax Biotechnology Co., Ltd.